Sun Pharmaceutical Industries today said it has received US health regulator’s approval to market generic version of Doxil injection, used in treating ovarian cancer in the American market.
The Mumbai-headquartered firm, in a statement, said its subsidiary has received approval from US food and Drug Administration (USFDA), and US food and Drug Administration (USFDA) for its Doxorubicin HCl Liposome Injection.
“This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC,” the company said.
Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 per cent from their previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.